Neuroscience Department, The Cyprus Institute of Neurology and Genetics and Cyprus School of Molecular Medicine, Nicosia, Cyprus.
Neuroscience Department, The Cyprus Institute of Neurology and Genetics and Cyprus School of Molecular Medicine, Nicosia, Cyprus; Center for Neuromuscular Disorders, The Cyprus Institute of Neurology and Genetics and Cyprus School of Molecular Medicine, Nicosia, Cyprus.
Neurosci Lett. 2021 Jan 18;742:135357. doi: 10.1016/j.neulet.2020.135357. Epub 2020 Nov 26.
Peripheral neuropathies of genetic etiology are a very diverse group of disorders manifesting either as non-syndromic inherited neuropathies without significant manifestations outside the peripheral nervous system, or as part of a systemic or syndromic genetic disorder. The former and most frequent group is collectively known as Charcot-Marie-Tooth disease (CMT), with prevalence as high as 1:2,500 world-wide, and has proven to be genetically highly heterogeneous. More than 100 different genes have been identified so far to cause various CMT forms, following all possible inheritance patterns. CMT causative genes belong to several common functional pathways that are essential for the integrity of the peripheral nerve. Their discovery has provided insights into the normal biology of axons and myelinating cells, and has highlighted the molecular mechanisms including both loss of function and gain of function effects, leading to peripheral nerve degeneration. Demyelinating neuropathies result from dysfunction of genes primarily affecting myelinating Schwann cells, while axonal neuropathies are caused by genes affecting mostly neurons and their long axons. Furthermore, mutation in genes expressed outside the nervous system, as in the case of inherited amyloid neuropathies, may cause peripheral neuropathy resulting from accumulation of β-structured amyloid fibrils in peripheral nerves in addition to various organs. Increasing insights into the molecular-genetic mechanisms have revealed potential therapeutic targets. These will enable the development of novel therapeutics for genetic neuropathies that remain, in their majority, without effective treatment.
遗传性周围神经病是一组非常多样化的疾病,表现为非综合征遗传性周围神经病,在外周神经系统无明显表现,或作为系统性或综合征性遗传疾病的一部分。前者和最常见的组统称为腓骨肌萎缩症(CMT),全球患病率高达 1:2500,并且已被证明具有高度遗传异质性。迄今为止,已经确定了 100 多个不同的基因导致各种 CMT 形式,遵循所有可能的遗传模式。CMT 致病基因属于几个常见的功能途径,这些途径对周围神经的完整性至关重要。它们的发现为轴突和髓鞘细胞的正常生物学提供了深入的了解,并强调了包括功能丧失和功能获得效应在内的分子机制,导致周围神经变性。脱髓鞘神经病是由主要影响髓鞘施万细胞的基因功能障碍引起的,而轴索性神经病是由主要影响神经元及其长轴突的基因引起的。此外,如遗传性淀粉样神经病的情况,在神经系统外表达的基因的突变可能导致除各种器官外,β 结构的淀粉样纤维在周围神经中的积累导致的周围神经病。对分子遗传机制的深入了解揭示了潜在的治疗靶点。这将为大多数仍缺乏有效治疗的遗传性神经病变开发新的治疗方法。